EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027

Lifesciences | Pharmaceuticals

EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027

Market By Dosages, Formulation And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

The Europe hyperphosphatemia drugs market is expected to grow rapidly at a CAGR of 16.11% during the forecasting years 2019-2027, as per a research conducted by Triton.

Countries that have been analyzed in the European hyperphosphatemia drugs market:

•           United Kingdom

•           Germany

•           France

•           Italy

•           Spain

•           Russia

•           Rest of Europe

In the European region, the bone mineral density measurement is underutilized due to various reasons such as limitations in personnel acceptable to execute scans, imperfect availability of densitometers, limited or nonexistent reimbursements and low awareness regarding the benefits of BMD testing.

Report scope can be customized per your requirements. Request For Customization

Increasing osteoporosis disease cases in France have become a major driving factor in strengthening the demand for the hyperphosphatemia drugs market. The occurrences of diagnosed cases of osteoporosis were around 9.7%, and are expected to increase linearly as the population ages. Also, the incidences of osteoporotic vertebral fractures are increasing in the country. This would result in substantial morbidity, which might create a negative impact on life expectancy. Due to the rising aging population, the occurrence of low bone mass and osteoporosis diseases is anticipated to increase over the years.

The change in dietary habits is driving the hyperphosphatemia drug market in Germany. Foods high in proteins are naturally high in phosphorus, which contributes to higher phosphorus intake from an average diet. Foods containing phosphates, such as meat, dairy items, fast food, soft drinks, nuts, seeds, chocolate and processed food are increasing the demand for the hyperphosphatemia drugs market in Germany. Consumption of such processed foods can lead to an increase in the phosphorus levels in the blood. This high level of phosphate creates an electrolyte disturbance and thus causes hyperphosphatemia in the body. Processed food such as meat is better absorbed by the gastrointestinal tract as compared to natural food. Common salt used is highly rich in calcium phosphate. Such calcium-fortified foods can also increase phosphorus intake in our body.

RoE market is mainly driven by the aging population, expanding incidences of osteoporosis, obesity, poor dietary habits of people increasingly inclining towards consuming unhealthy & fat-rich foods and the growing number of people undergoing dialysis. Importantly, the aging population can be considered as the most crucial reason for the rising prevalence of hyperphosphatemia disorders that is driving the growth in the European market.

 

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    EUROPE HYPERPHOSPHATEMIA DRUGS MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCE MODEL

2.2.1.   THREAT OF NEW ENTRANTS

2.2.2.   BARGAINING POWER OF BUYERS

2.2.3.   BARGAINING POWER OF SUPPLIERS

2.2.4.   THREAT OF SUBSTITUTE PRODUCT

2.2.5.   INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. KEY BUYING OUTLOOK

2.5. KEY INSIGHTS

2.6. KEY MARKET TRENDS

2.7. GUIDELINES RELATED TO THE PHOSPHATE BINDERS

2.8. MARKET DRIVERS

2.8.1.   CHRONIC DISORDERS ARE INCREASING RAPIDLY

2.8.2.   INCREASE IN PUBLIC COGNIZANCE

2.8.3.   INCREASE IN GERIATRIC POPULATION

2.9. MARKET RESTRAINTS

2.9.1.   SIDE-EFFECTS RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS

2.9.2.   STRICT FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS

2.10.            MARKET OPPORTUNITIES

2.10.1.                RISE IN THE AGING POPULATION

2.11.            MARKET CHALLENGES

2.11.1.                ALTERNATIVE DIALYSIS TECHNIQUES

2.11.2.                ACCESSIBILITY OF DRUGS IS LIMITED

2.11.3.                NON-ADHERENCE TO TREATMENT REGIMES

3.    HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK - BY DOSAGES

3.1. SOLID

3.1.1.   TABLET

3.1.2.   POWDER

3.2. LIQUID

3.2.1.   SOLUTION

4.    HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK - BY FORMULATION

4.1.1.   CALCIUM-BASED PHOSPHATE BINDERS

4.1.2.   ALUMINUM-BASED PHOSPHATE BINDERS

4.1.3.   MAGNESIUM-BASED PHOSPHATE BINDERS

4.1.4.   IRON-BASED PHOSPHATE BINDERS

4.1.5.   OTHER PHOSPHATE BINDERS

5.    HYPERPHOSPHATEMIA DRUGS MARKET - REGIONAL OUTLOOK

5.1. EUROPE

5.1.1.   COUNTRY ANALYSIS

5.1.1.1.      UNITED KINGDOM

5.1.1.2.      FRANCE

5.1.1.3.      GERMANY

5.1.1.4.      SPAIN

5.1.1.5.      ITALY

5.1.1.6.      RUSSIA

5.1.1.7.      REST OF EUROPE

6.    COMPETITIVE LANDSCAPE

6.1. JOHNSON AND JOHNSON

6.2. ZERIA PHARMACEUTICAL

6.3. AMAG PHARMACEUTICALS

6.4. SANOFI

6.5. BRUNO FARMACEUTICI S.P.A.

6.6. ROCHE DIAGNOSTICS CORPORATION

6.7. ROYAL DSM N.V.

6.8. SHIRE

6.9. CIPLA

6.10.            ULTRAGENYX PHARMACEUTICAL, INC.

6.11.            FERMENTA BIOTECH, LTD.

6.12.            BIOTECH PHARMACAL

6.13.            SUN PHARMACEUTICAL INDUSTRIES, LTD.

6.14.            KERYX BIOPHARMACEUTICALS, INC.

6.15.            FRESENIUS MEDICAL CARE

6.16.            PFIZER, INC.

7.    METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

List of table

TABLE 1        EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

TABLE 2        PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3        EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 ($ MILLION)

TABLE 4        DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5        EUROPE HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 ($ MILLION)

List of Figures

FIGURE 1      PORTER’S FIVE FORCES MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2      IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3      RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4      EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 5      EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 6      EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 7      EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 8      EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 ($ MILLION)

FIGURE 9      EUROPE HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10   EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 11   UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 12   FRANCE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 13   GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 14   SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 15   ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 16   RUSSIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 17   REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;